Creates ultra-small (~15 kDa) fully synthetic single-domain antibody therapeutics and antibody–drug conjugates from human VH and humanized VHH libraries to enable deep tissue penetration and precise target engagement. Targets complex, underserved diseases using predictive target identification, antibody engineering/optimization, and rapid preclinical-to-clinical translation for co-development and licensing.